Loading…
Bioverse sold unapproved and misbranded compounded semaglutide and tirzepatide products directly to consumers online, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company made false or misleading claims that its compounded products contained "the same active ingredient" as FDA-approved drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, implying equivalence to approved medications when compounded drugs are not FDA-approved. By marketing these products with comparative claims to approved pharmaceuticals, Bioverse introduced misbranded drugs into interstate commerce in violation of section 301(a) of the FDCA.